CR20190567A - Derivados de indol n-sustituidos - Google Patents

Derivados de indol n-sustituidos

Info

Publication number
CR20190567A
CR20190567A CR20190567A CR20190567A CR20190567A CR 20190567 A CR20190567 A CR 20190567A CR 20190567 A CR20190567 A CR 20190567A CR 20190567 A CR20190567 A CR 20190567A CR 20190567 A CR20190567 A CR 20190567A
Authority
CR
Costa Rica
Prior art keywords
indole derivatives
substituted indole
formula
derivatives
prostaglandin
Prior art date
Application number
CR20190567A
Other languages
English (en)
Spanish (es)
Inventor
Sylvia Richard-Bildstein
Isabelle Lyother
Heinz Fretz
Thierry Sifferlen
Julien Pothier
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CR20190567A publication Critical patent/CR20190567A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR20190567A 2017-05-18 2018-05-17 Derivados de indol n-sustituidos CR20190567A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2017062008 2017-05-18
PCT/EP2018/062865 WO2018210995A1 (en) 2017-05-18 2018-05-17 N-substituted indole derivatives

Publications (1)

Publication Number Publication Date
CR20190567A true CR20190567A (es) 2020-02-10

Family

ID=62186481

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190567A CR20190567A (es) 2017-05-18 2018-05-17 Derivados de indol n-sustituidos

Country Status (32)

Country Link
US (2) US20200069686A1 (enExample)
EP (1) EP3625224B1 (enExample)
JP (1) JP7065117B2 (enExample)
KR (1) KR102650756B1 (enExample)
CN (1) CN110621666A (enExample)
AR (1) AR111806A1 (enExample)
AU (1) AU2018269667B2 (enExample)
BR (1) BR112019024114A2 (enExample)
CA (1) CA3063637A1 (enExample)
CL (1) CL2019003257A1 (enExample)
CO (1) CO2019010804A2 (enExample)
CR (1) CR20190567A (enExample)
CY (1) CY1124528T1 (enExample)
DK (1) DK3625224T3 (enExample)
EA (1) EA039630B1 (enExample)
ES (1) ES2894124T3 (enExample)
HR (1) HRP20211532T1 (enExample)
HU (1) HUE056406T2 (enExample)
IL (1) IL270616B (enExample)
LT (1) LT3625224T (enExample)
MA (1) MA49127B1 (enExample)
MX (1) MX394108B (enExample)
PE (1) PE20191787A1 (enExample)
PH (1) PH12019502562B1 (enExample)
PL (1) PL3625224T3 (enExample)
PT (1) PT3625224T (enExample)
RS (1) RS62441B1 (enExample)
SG (1) SG11201908660RA (enExample)
SI (1) SI3625224T1 (enExample)
TW (1) TWI768043B (enExample)
UA (1) UA124748C2 (enExample)
WO (1) WO2018210995A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
WO2018210992A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
EP3625227B1 (en) 2017-05-18 2022-09-14 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as pge2 receptor modulators
AR111808A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
SI3625222T1 (sl) 2017-05-18 2021-11-30 Idorsia Pharmaceuticals Ltd Derivati fenila kot modulatorji receptorja pge2
WO2021060281A1 (ja) * 2019-09-24 2021-04-01 Ａｇｃ株式会社 プロスタグランジンｅ２レセプターｅｐ２／ｅｐ４デュアルアンタゴニスト
CN115697317A (zh) * 2020-04-08 2023-02-03 株式会社AskAt Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用
EP4245301A4 (en) 2020-11-13 2024-08-21 ONO Pharmaceutical Co., Ltd. TREATMENT OF CANCER BY COMBINED USE OF AN EP4 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR
WO2025229177A1 (en) 2024-05-02 2025-11-06 Idorsia Pharmaceuticals Ltd Crystalline forms of an n-substituted indole derivative

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60038902D1 (de) 2000-03-24 2008-06-26 Asterand Uk Ltd Verwendung von prostanoid-ep4-rezeptor-antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonisten
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
MXPA04009960A (es) 2002-04-12 2004-12-13 Pfizer Compuestos de pirazol como agentes anti-inflamatorios y analgesicos.
AU2003216579A1 (en) 2002-04-12 2003-10-27 Pfizer Inc. Imidazole compounds as anti-inflammatory and analgesic agents
AU2003233297A1 (en) 2002-05-23 2003-12-12 Theratechnologies Inc Antagonistic peptides of prostaglandin e2 receptor subtype ep4
ATE396182T1 (de) 2003-01-29 2008-06-15 Asterand Uk Ltd Hemmstoffe des ep4-rezeptors
CN1871240B (zh) * 2003-08-26 2012-11-07 帝人制药株式会社 吡咯并嘧啶酮衍生物
KR100747401B1 (ko) 2003-09-03 2007-08-08 화이자 인코포레이티드 프로스타글란딘 ｅ2 길항제로서의 페닐 또는 피리딜 아미드 화합물
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
EP1756042B8 (en) 2004-05-04 2014-06-04 RaQualia Pharma Inc Substituted methyl aryl or heteroaryl amide compounds
AP2006003769A0 (en) 2004-05-04 2006-10-31 Pfizer Ortho substituted aryl or heteroaryl amide compounds
GT200500284A (es) 2004-10-15 2006-03-27 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
WO2006122403A1 (en) 2005-05-19 2006-11-23 Merck Frosst Canada Ltd. Quinoline derivatives as ep4 antagonists
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
US7968578B2 (en) 2006-04-24 2011-06-28 Merck Frosst Canada Ltd. Indole amide derivatives as EP4 receptor antagonists
EP2035376B1 (en) 2006-06-12 2014-08-27 Merck Canada Inc. Indoline amide derivatives as ep4 receptor ligands
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
AR061974A1 (es) 2006-07-14 2008-08-10 Novartis Ag Derivados de pirimidina como inhibidores de alk, composiciones farmaceuticas y procesos de obtencion
EP2054401B1 (en) 2006-08-11 2013-05-01 Merck Canada Inc. Thiophenecarboxamide derivatives as ep4 receptor ligands
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
CN101622230B (zh) 2007-02-26 2012-08-22 默克弗罗斯特加拿大有限公司 作为ep4受体拮抗剂的吲哚和二氢吲哚环丙基酰胺衍生物
US8030489B2 (en) 2007-03-26 2011-10-04 Astellas Pharma Inc. Ornithine derivative
CN101636385B (zh) 2007-03-26 2012-09-05 默克弗罗斯特加拿大有限公司 作为ep4受体拮抗剂的萘和喹啉磺酰脲衍生物
EP2014657A1 (de) * 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine als Modulatoren des EP2-Rezeptors
WO2009005076A1 (ja) 2007-07-03 2009-01-08 Astellas Pharma Inc. アミド化合物
JP5375824B2 (ja) 2008-05-14 2013-12-25 アステラス製薬株式会社 アミド化合物
US8404736B2 (en) 2008-08-14 2013-03-26 Beta Pharma Canada Inc. Heterocyclic amide derivatives as EP4 receptor antagonists
CN102164942B (zh) 2008-09-19 2017-02-15 生物科技研究有限公司 三萜系化合物及其使用的方法
EP2346866B1 (en) 2008-09-25 2013-11-27 Merck Canada Inc. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
MX2012013274A (es) 2010-05-21 2013-05-28 Chemilia Ab Novedosos derivados de la pirimidina.
ME02575B (me) 2010-09-21 2017-06-20 Eisai R&D Man Co Ltd Farmaceutska kompozicija
CN106046158A (zh) 2010-09-29 2016-10-26 株式会社Nb健康研究所 针对人前列腺素e2 受体ep4 的抗体
EP2649061B1 (en) 2010-12-10 2015-05-13 Rottapharm Biotech S.r.l. Pyridine amide derivatives as ep4 receptor antagonists
WO2012103071A2 (en) 2011-01-25 2012-08-02 Eisai R&D Management Co., Ltd. Compounds and compositions
JP5886411B2 (ja) * 2011-03-24 2016-03-16 ノビガ・リサーチ・エービーＮｏｖｉｇａ Ｒｅｓｅａｒｃｈ ＡＢ 新規のピリミジン誘導体
RU2565596C2 (ru) 2011-07-04 2015-10-20 Роттафарм Биотек С.Р.Л. Производные циклических аминов в качестве антагонистов рецептора ер4
EP2554662A1 (en) 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
US20150004175A1 (en) 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
IN2014KN02601A (enExample) 2012-04-24 2015-05-08 Vertex Pharma
AR091429A1 (es) 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
TWI572597B (zh) 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基－苯甲酸化合物
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2765128A1 (en) 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
TW201443004A (zh) 2013-02-15 2014-11-16 Lilly Co Eli 苯氧基乙氧基化合物
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
HUE039015T2 (hu) 2013-06-12 2018-12-28 Kaken Pharma Co Ltd 4-Alkinil-imidazol-származék és ezt hatóanyagként tartalmazó gyógyszerkészítmény
CN105705489B (zh) 2013-09-04 2019-04-26 百时美施贵宝公司 用作免疫调节剂的化合物
RS57508B1 (sr) 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,2,4-derivati oksadiazola kao imunomodulatori
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
BR112016008423B1 (pt) 2013-10-17 2022-02-22 Vertex Pharmaceuticals Incorporated Composto, composição farmacêutica compreendendo o mesmo e seu uso
LT3083562T (lt) 2013-12-17 2018-01-10 Eli Lilly & Company Fenoksietilo cikliniai amino dariniai ir jų aktyvumas kaip ep4 receptoriaus moduliatorių
ES2727329T3 (es) 2013-12-17 2019-10-15 Lilly Co Eli Compuestos de ácido dimetilbenzoico
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
CA2949961C (en) 2014-05-23 2023-09-19 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of cancer
WO2016021742A1 (en) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
WO2016054807A1 (en) 2014-10-10 2016-04-14 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
TWI783617B (zh) 2015-01-09 2022-11-11 日商小野藥品工業股份有限公司 三環性螺化合物之用途
DK3325490T3 (da) 2015-07-23 2020-02-03 Takeda Pharmaceuticals Co 1-substituerede 1,2,3,4-tetrahydro-1,7-naphthyridin-8-aminderivater og deres anvendelse som ep4-receptorantagonister
MX390051B (es) 2015-10-16 2025-03-20 Eisai R&D Man Co Ltd Antagonistas de ep4.

Also Published As

Publication number Publication date
TW201900637A (zh) 2019-01-01
KR20200006589A (ko) 2020-01-20
TWI768043B (zh) 2022-06-21
DK3625224T3 (da) 2021-11-08
US20230165859A1 (en) 2023-06-01
EP3625224A1 (en) 2020-03-25
MX2019013639A (es) 2020-01-21
ES2894124T3 (es) 2022-02-11
US20200069686A1 (en) 2020-03-05
LT3625224T (lt) 2021-10-25
SI3625224T1 (sl) 2021-11-30
AU2018269667B2 (en) 2022-02-03
IL270616B (en) 2022-01-01
CO2019010804A2 (es) 2019-10-09
KR102650756B1 (ko) 2024-03-22
EA201992679A1 (ru) 2020-05-06
EA039630B1 (ru) 2022-02-18
CY1124528T1 (el) 2022-07-22
PE20191787A1 (es) 2019-12-24
AU2018269667A1 (en) 2019-10-24
WO2018210995A1 (en) 2018-11-22
HRP20211532T1 (hr) 2022-01-07
UA124748C2 (uk) 2021-11-10
JP2020520359A (ja) 2020-07-09
PH12019502562A1 (en) 2020-07-20
SG11201908660RA (en) 2019-10-30
BR112019024114A2 (pt) 2020-06-02
HUE056406T2 (hu) 2022-02-28
AR111806A1 (es) 2019-08-21
EP3625224B1 (en) 2021-08-04
MX394108B (es) 2025-03-21
MA49127B1 (fr) 2022-05-31
JP7065117B2 (ja) 2022-05-11
PT3625224T (pt) 2021-10-06
MA49127A (fr) 2021-05-26
PL3625224T3 (pl) 2022-01-10
RS62441B1 (sr) 2021-11-30
CA3063637A1 (en) 2018-11-22
PH12019502562B1 (en) 2024-06-14
CL2019003257A1 (es) 2020-03-27
CN110621666A (zh) 2019-12-27

Similar Documents

Publication Publication Date Title
MY195888A (en) N-Substituted Indole Derivatives As Pge2 Receptor Modulators
PH12019502562A1 (en) N-substituted indole derivatives
MX2021004000A (es) Derivados de piperidina.
MY169986A (en) Benzimidazole-proline derivatives
PH12022550338A1 (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
MX389592B (es) Moduladores alostericos positivos del receptor m1 muscarinico
SA522431777B1 (ar) مشتقات ألفا -d- جالاكتو بيرانوسيد
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
PH12015502632A1 (en) Cxcr7 receptor modulators
JOP20190183B1 (ar) معدِلات مستقبلات الاستروجين
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
PH12021553178A1 (en) Pyridin-3-yl derivatives
MX2020013291A (es) Derivados de piridinilo alcoxisustituido como antagonistas del receptor lpa1 y su uso en el tratamiento de la fibrosis.
NZ763341A (en) Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
NZ764004A (en) Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators
TN2018000175A1 (en) Indane derivatives as mglur7 modulators
MX2021004471A (es) Derivados de pirrolo-pididazina como moduladores alostéricos positivos del receptor muscarínico m1.
TH1901007033A (th) อนุพันธ์ของอินโดลที่ถูกแทนที่แบบ n
NZ764561A (en) Substituted azacycles as muscarinic m1 receptor positive allosteric modulators